Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency
Makaleler > Tam Makale · 2015
Yazarlar: Claudia WEHR, Andrew R. GENNERY, Caroline Lindemans, Ansgar Schulz, Manfred Hoenig, Reinhard MARKS, Mike Recher, Bernd GRUHN, Andreas Holbro, Ingmar Heijnen, Deborah MEYER, Goetz GRIGOLEIT, Hermann EINSELE, Ulrich BAUMANN, Thorsten WITTE, Karl-Walter SYKORA, Sigune GOLDACKER, Lorena REGAIRAZ, Serap AKSOYLAR, Fatma Ömür ARDENİZ, Marco ZECCA, Przemyslaw ZDZIARSKI, Isabelle MEYTS, Susanne MATTHES-MARTIN, Kohsuke IMAI, Chikako KAMAE, Adele FIELDING, Suranjith SENEVIRATNE, Nizar MAHLAOUI, Mary A. SLATTER, Tayfun GUNGOR, Peter D. ARKWRIGHT, Joris VAN MONTFRANS, Kathleen E. SULLIVAN, Bodo GRIMBACHER, Andrew CANT, Hans-Hartmut PETER, Juergen FINKE, H. Bobby GASPAR, Klaus WARNATZ, Marta RIZZI
Journal of Allergy and Clinical Immunology, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2015, cilt 135, ss 988-997.e6
DOI: 10.1016/j.jaci.2014.11.029
Özet
Background: Common variable immunodeficiency (CVID) is usually well controlled with immunoglobulin substitution and immunomodulatory drugs. A subgroup of patients has a complicated disease course with high mortality. For these patients, investigation of more invasive, potentially curative treatments, such as allogeneic hematopoietic stem cell transplantation (HSCT), is warranted.